BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 28949776)

  • 1. Beneficial effects of bile acid receptor agonists in pulmonary disease models.
    Comeglio P; Morelli A; Adorini L; Maggi M; Vignozzi L
    Expert Opin Investig Drugs; 2017 Nov; 26(11):1215-1228. PubMed ID: 28949776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression.
    Erice O; Labiano I; Arbelaiz A; Santos-Laso A; Munoz-Garrido P; Jimenez-Agüero R; Olaizola P; Caro-Maldonado A; Martín-Martín N; Carracedo A; Lozano E; Marin JJ; O'Rourke CJ; Andersen JB; Llop J; Gómez-Vallejo V; Padro D; Martin A; Marzioni M; Adorini L; Trauner M; Bujanda L; Perugorria MJ; Banales JM
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1335-1344. PubMed ID: 28916388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic effects of the selective farnesoid X receptor agonist obeticholic acid in a monocrotaline-induced pulmonary hypertension rat model.
    Comeglio P; Filippi S; Sarchielli E; Morelli A; Cellai I; Corno C; Adorini L; Vannelli GB; Maggi M; Vignozzi L
    J Endocrinol Invest; 2019 Aug; 42(8):951-965. PubMed ID: 30674010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity.
    Wang XX; Wang D; Luo Y; Myakala K; Dobrinskikh E; Rosenberg AZ; Levi J; Kopp JB; Field A; Hill A; Lucia S; Qiu L; Jiang T; Peng Y; Orlicky D; Garcia G; Herman-Edelstein M; D'Agati V; Henriksen K; Adorini L; Pruzanski M; Xie C; Krausz KW; Gonzalez FJ; Ranjit S; Dvornikov A; Gratton E; Levi M
    J Am Soc Nephrol; 2018 Jan; 29(1):118-137. PubMed ID: 29089371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-fibrotic effects of chronic treatment with the selective FXR agonist obeticholic acid in the bleomycin-induced rat model of pulmonary fibrosis.
    Comeglio P; Filippi S; Sarchielli E; Morelli A; Cellai I; Corcetto F; Corno C; Maneschi E; Pini A; Adorini L; Vannelli GB; Maggi M; Vignozzi L
    J Steroid Biochem Mol Biol; 2017 Apr; 168():26-37. PubMed ID: 28115235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiopulmonary protective effects of the selective FXR agonist obeticholic acid in the rat model of monocrotaline-induced pulmonary hypertension.
    Vignozzi L; Morelli A; Cellai I; Filippi S; Comeglio P; Sarchielli E; Maneschi E; Vannelli GB; Adorini L; Maggi M
    J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt B):277-292. PubMed ID: 27425465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism.
    Pathak P; Liu H; Boehme S; Xie C; Krausz KW; Gonzalez F; Chiang JYL
    J Biol Chem; 2017 Jun; 292(26):11055-11069. PubMed ID: 28478385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. INT-767 improves histopathological features in a diet-induced
    Roth JD; Feigh M; Veidal SS; Fensholdt LK; Rigbolt KT; Hansen HH; Chen LC; Petitjean M; Friley W; Vrang N; Jelsing J; Young M
    World J Gastroenterol; 2018 Jan; 24(2):195-210. PubMed ID: 29375205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR.
    Jadhav K; Xu Y; Xu Y; Li Y; Xu J; Zhu Y; Adorini L; Lee YK; Kasumov T; Yin L; Zhang Y
    Mol Metab; 2018 Mar; 9():131-140. PubMed ID: 29361497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dual agonist of farnesoid X receptor (FXR) and the G protein-coupled receptor TGR5, INT-767, reverses age-related kidney disease in mice.
    Wang XX; Luo Y; Wang D; Adorini L; Pruzanski M; Dobrinskikh E; Levi M
    J Biol Chem; 2017 Jul; 292(29):12018-12024. PubMed ID: 28596381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis.
    Ho PP; Steinman L
    Proc Natl Acad Sci U S A; 2016 Feb; 113(6):1600-5. PubMed ID: 26811456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting FXR in cholestasis: hype or hope.
    Fiorucci S; Distrutti E; Ricci P; Giuliano V; Donini A; Baldelli F
    Expert Opin Ther Targets; 2014 Dec; 18(12):1449-59. PubMed ID: 25200104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gluco-Metabolic Effects of Pharmacotherapy-Induced Modulation of Bile Acid Physiology.
    Brønden A; Knop FK
    J Clin Endocrinol Metab; 2020 Jan; 105(1):. PubMed ID: 31630179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bile acids: emerging role in management of liver diseases.
    Asgharpour A; Kumar D; Sanyal A
    Hepatol Int; 2015 Oct; 9(4):527-33. PubMed ID: 26320013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist.
    Rizzo G; Passeri D; De Franco F; Ciaccioli G; Donadio L; Rizzo G; Orlandi S; Sadeghpour B; Wang XX; Jiang T; Levi M; Pruzanski M; Adorini L
    Mol Pharmacol; 2010 Oct; 78(4):617-30. PubMed ID: 20631053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bile Acid G Protein-Coupled Membrane Receptor TGR5 Modulates Aquaporin 2-Mediated Water Homeostasis.
    Li S; Qiu M; Kong Y; Zhao X; Choi HJ; Reich M; Bunkelman BH; Liu Q; Hu S; Han M; Xie H; Rosenberg AZ; Keitel V; Kwon TH; Levi M; Li C; Wang W
    J Am Soc Nephrol; 2018 Nov; 29(11):2658-2670. PubMed ID: 30305310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of FXR and TGR5 in reversing and preventing progression of Western diet-induced hepatic steatosis, inflammation, and fibrosis in mice.
    Wang XX; Xie C; Libby AE; Ranjit S; Levi J; Myakala K; Bhasin K; Jones BA; Orlicky DJ; Takahashi S; Dvornikov A; Kleiner DE; Hewitt SM; Adorini L; Kopp JB; Krausz KW; Rosenberg A; McManaman JL; Robertson CE; Ir D; Frank DN; Luo Y; Gonzalez FJ; Gratton E; Levi M
    J Biol Chem; 2022 Nov; 298(11):102530. PubMed ID: 36209823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual Agonist of Farnesoid X Receptor and Takeda G Protein-Coupled Receptor 5 Inhibits Hepatitis B Virus Infection In Vitro and In Vivo.
    Ito K; Okumura A; Takeuchi JS; Watashi K; Inoue R; Yamauchi T; Sakamoto K; Yamashita Y; Iguchi Y; Une M; Wakita T; Umezawa K; Yoneda M
    Hepatology; 2021 Jul; 74(1):83-98. PubMed ID: 33434356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO⁻₃ output.
    Baghdasaryan A; Claudel T; Gumhold J; Silbert D; Adorini L; Roda A; Vecchiotti S; Gonzalez FJ; Schoonjans K; Strazzabosco M; Fickert P; Trauner M
    Hepatology; 2011 Oct; 54(4):1303-12. PubMed ID: 22006858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bile acid receptors and the kidney.
    Herman-Edelstein M; Weinstein T; Levi M
    Curr Opin Nephrol Hypertens; 2018 Jan; 27(1):56-62. PubMed ID: 29045336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.